Percheron Therapeutics

(OTC) ATHJF

Current PriceN/A

Market CapN/A

Since IPO (2007)-96%

5 Year-99%

1 Year-50%

1 Month-60%

Percheron Therapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

A$4.55M

Net Income (TTM)

-A$23.30M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

ATHJF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Percheron Therapeutics

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

James Stuart Garner, PhD, MBA

Website

www.PercheronTx.com

Headquarters

Toorak, VIC 3142, AU

ATHJF Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-1%

Return on Capital

-2%

Return on Assets

-1%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

A$2.91M

Operating Income

-A$11.83M

EBITDA

-A$11.90M

Operating Cash Flow

-A$10.12M

Capital Expenditure

-A$3.61K

Free Cash Flow

-A$10.12M

Cash & ST Invst.

A$11.87M

Total Debt

A$39.87K

Percheron Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2024YOY CHG

Revenue

A$1.77M

+16.5%

Gross Profit

A$1.75M

+17.0%

Gross Margin

98.92%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-A$7.18M

-153.6%

EBITDA

-A$7.17M

-151.1%

Quarterly Fundamentals

Name

Q4 2024YOY CHG

Net Cash

A$11.83M

-37.8%

Accounts Receivable

A$2.51M

+36.3%

Inventory

A$0.00

-100.0%

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$39.87K

-57.6%

Return on Assets

-1.20%

N/A

Return on Invested Capital

-1.58%

N/A

Free Cash Flow

-A$5.37M

-27.1%

Operating Cash Flow

-A$5.37M

-27.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

OCELOrganicell Regenerative Medicine, Inc.

OCELOrganicell Regenerative Medicine, Inc.$2.74-0.27%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ASTCAstrotech

ASTCAstrotech$13.81+4.59%

ONDSOndas

ONDSOndas$10.80+0.11%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.92+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$16.28+0.03%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$81.67-0.00%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$39.44+0.00%

SIDUSidus Space

SIDUSidus Space$6.09-0.02%

Questions About ATHJF

What is the current price of Percheron Therapeutics?

Percheron Therapeutics is trading at N/A per share.

What is the 52-week range for Percheron Therapeutics?

Over the past 52 weeks, Percheron Therapeutics has traded between N/A and N/A.

How much debt does Percheron Therapeutics have?

As of the most recent reporting period, Percheron Therapeutics reported total debt of A$16.95K.

How much cash does Percheron Therapeutics have on hand?

Percheron Therapeutics reported A$404.91K in cash and cash equivalents in its most recent financial results.

What is Percheron Therapeutics’s dividend yield?

Percheron Therapeutics does not currently have a dividend yield.

Percheron Therapeutics

Percheron Therapeutics Financials at a Glance

ATHJF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Percheron Therapeutics

ATHJF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Percheron Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ATHJF

What is the current price of Percheron Therapeutics?

What is the 52-week range for Percheron Therapeutics?

How much debt does Percheron Therapeutics have?

How much cash does Percheron Therapeutics have on hand?

What is Percheron Therapeutics’s dividend yield?

Premium Investing Services